Bruker Corp (BRKR)
NASDAQ:BRKR
Want to see BRKR full AI Analyst Report?
Top Page
Bruker
(NASDAQ:BRKR)
Select Model
Select Model
Rating:51Neutral
Price Target:
$37.00
▼(-9.09% Downside)
Action:ReiteratedDate:04/29/26
The score is held back primarily by weakened TTM fundamentals (revenue decline, margin compression, and materially softer cash generation) and a technically weak price trend (below major moving averages). The latest earnings call provides a partial offset with improving order/backlog signals and FY2026 guidance for margin expansion and cost savings, but valuation support is limited given a negative P/E and a low dividend yield.
Positive Factors
Growing aftermarket & recurring revenue
Higher aftermarket contribution raises recurring revenue mix and reduces reliance on lumpy instrument sales. A larger installed base drives service, consumables, and software revenue that typically sustains margins and cash flow across capital‑spend cycles, improving long‑term revenue visibility.
Negative Factors
Persistent organic revenue declines
Ongoing organic declines indicate demand weakness in core end markets (academic, government, some instrument lines). Reliance on M&A and FX to offset organic shortfalls raises execution risk and can mask slower underlying adoption, limiting sustainable top‑line growth without recovery in underlying end markets.
Read all positive and negative factors
Positive Factors
Negative Factors
Growing aftermarket & recurring revenue
Higher aftermarket contribution raises recurring revenue mix and reduces reliance on lumpy instrument sales. A larger installed base drives service, consumables, and software revenue that typically sustains margins and cash flow across capital‑spend cycles, improving long‑term revenue visibility.
Read all positive factors
Bruker (BRKR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.60B
Dividend Yield0.42%
Average Volume (3M)1.98M
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth2.08%
EPS Growth-119.43%
CountryUS
Employees11,396
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.59
Shares Outstanding152,223,140
10 Day Avg. Volume1,683,342
30 Day Avg. Volume1,984,054
Financial Highlights & Ratios
PEG Ratio6.94
Price to Book (P/B)2.91
Price to Sales (P/S)2.08
P/FCF Ratio165.16
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue2.14
Enterprise Value/Gross Profit4.58
Enterprise Value/Ebitda24.71
Forecast
1Y Price Target
$42.88Price Target Upside5.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)2.11
Revenue Forecast (FY)$3.58B
Bruker Business Overview & Revenue Model
Company Description
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) L...
How the Company Makes Money
Bruker primarily makes money by selling scientific instruments and integrated analytical systems, complemented by recurring revenue from services, software, and consumables. Key revenue streams typically include: (1) Instrument and system sales: O...
Bruker Earnings Call Summary
Earnings Call Date:Feb 12, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Neutral
Balanced/Neutral: The company showed meaningful positives including a Q4 revenue beat, exceptional cash generation (Q4 operating cash flow of ~$230M, free cash flow $207M), strong order momentum (BSI book-to-bill >1.0, ~7 months backlog), large multiyear BEST orders (> $500M), and constructive FY2026 guidance with targeted margin expansion and raised cost-savings expectations. However, these positives are offset by material near-term challenges: persistent organic revenue declines (Q4 -5.1%, FY -3.7%), significant margin compression (Q4 non-GAAP operating margin down 240 bps), pressure from tariffs and FX, weak U.S. academic/government funding, and expected Q1 2026 organic decline. Taken together, the call presents a credible operational and financial recovery plan built on strong cash flow and order momentum, but also substantial short-term headwinds and execution/timing risks.Positive Updates
Q4 Revenue Beat and Reported Revenue
Q4 2025 reported revenue of $977.2M was roughly flat year-over-year and came in about $20M above company expectations; full-year 2025 reported revenue was $3.44B, up 2.1% versus 2024.
Negative Updates
Organic Revenue Declines
Organic revenue declined 5.1% in Q4 2025 and declined 3.7% for full-year 2025, with organic declines of 5.1% in both BSI and BEST in Q4; several groups and end markets saw mid- to high-single-digit organic weakness.
Read all updates
Q4-2025 Updates
Positive
Negative
Q4 Revenue Beat and Reported Revenue
Q4 2025 reported revenue of $977.2M was roughly flat year-over-year and came in about $20M above company expectations; full-year 2025 reported revenue was $3.44B, up 2.1% versus 2024.
Read all positive updates
Company Guidance
Bruker guided fiscal 2026 reported revenue of $3.57–$3.60 billion (growth 4%–5%), comprised of 1%–2% organic growth, ~1.5% from M&A and an estimated ~1.5% FX tailwind (implying ~2.5%–3.5% constant‑currency revenue growth), while Q1 2026 organic revenue is expected down mid‑single‑digits with organic growth resuming in Q2; they noted a BSI backlog of ~7 months and two consecutive quarters of BSI book‑to‑bill >1.0. Management expects non‑GAAP operating margin expansion of 250–300 bps in 2026 (including ~50 bps currency headwind, implying ~300–350 bps organic margin improvement versus FY2025’s 12.6%), non‑GAAP EPS of $2.10–$2.15 (15%–17% reported growth, ~8% / ~$0.15 FX headwind, implying 23%–25% CER EPS growth), and cost savings now expected to exceed the prior $100–$120M target (approaching ~$140M+ annualized); Q4 free cash flow was $207M.Bruker Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
66
Positive
Cash Flow
44
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.44B | 3.37B | 2.96B | 2.53B | 2.42B |
| Gross Profit | 1.57B | 1.65B | 1.51B | 1.31B | 1.21B |
| EBITDA | 287.50M | 438.60M | 675.50M | 518.70M | 497.10M |
| Net Income | -8.60M | 113.10M | 427.20M | 296.60M | 277.10M |
Balance Sheet | |||||
| Total Assets | 6.24B | 5.81B | 4.25B | 3.61B | 3.65B |
| Cash, Cash Equivalents and Short-Term Investments | 298.80M | 183.40M | 488.30M | 645.50M | 1.17B |
| Total Debt | 2.04B | 2.25B | 1.38B | 1.27B | 1.39B |
| Total Liabilities | 3.73B | 3.99B | 2.84B | 2.48B | 2.57B |
| Stockholders Equity | 2.46B | 1.78B | 1.38B | 1.11B | 1.07B |
Cash Flow | |||||
| Free Cash Flow | 43.30M | 136.00M | 243.20M | 145.20M | 190.40M |
| Operating Cash Flow | 134.10M | 251.30M | 350.10M | 274.40M | 282.40M |
| Investing Cash Flow | -196.50M | -1.76B | -326.00M | -251.60M | -192.40M |
| Financing Cash Flow | 135.10M | 1.23B | -193.40M | -415.30M | 318.70M |
Bruker Technical Analysis
Positive
40.70
Price Trends
37.61
Positive
42.77
Negative
39.67
Positive
Market Momentum
0.69
Negative
64.24
Neutral
79.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRKR, the sentiment is Positive. The current price of 40.7 is above the 20-day moving average (MA) of 36.87, above the 50-day MA of 37.61, and above the 200-day MA of 39.67, indicating a bullish trend. The MACD of 0.69 indicates Negative momentum. The RSI at 64.24 is Neutral, neither overbought nor oversold. The STOCH value of 79.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRKR.
Bruker Risk Analysis
Bruker disclosed 42 risk factors in its most recent earnings report. Bruker reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bruker Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $12.34B | 21.94 | 12.40% | ― | 16.65% | 425.13% | |
68 Neutral | $3.34B | -13.83 | -21.49% | ― | 11.08% | -485.09% | |
65 Neutral | $7.05B | -3.56 | 10.86% | ― | 1.92% | ― | |
62 Neutral | $2.86B | 45.09 | 6.05% | ― | 5.48% | 77.43% | |
62 Neutral | $8.21B | -78.94 | -26.46% | ― | 36.30% | -42.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $5.60B | -831.55 | -0.40% | 0.42% | 2.08% | -119.43% |
* Healthcare Sector Average
BRKR
Bruker
36.79
-3.72
-9.19%
BIO
Bio-Rad Laboratories
256.55
16.36
6.81%
ITGR
Integer Holdings
84.03
-32.52
-27.90%
GMED
Globus Medical
91.34
20.84
29.56%
GKOS
Glaukos
140.22
53.36
61.43%
LIVN
LivaNova
61.00
24.72
68.14%
Bruker Corporate Events
Dividends
Bruker Declares Quarterly Dividend on Preferred Stock
Positive
Apr 28, 2026
Bruker Corporation announced that its Board of Directors declared a quarterly cash dividend on the company’s 6.375% Mandatory Convertible Preferred Stock, Series A, of $3.9844 per share. The dividend was declared on April 28, 2026, and is pa...
Executive/Board Changes
Bruker Announces Planned Transition of BioSpin Group President
Neutral
Apr 10, 2026
On April 6, 2026, Bruker Corporation and Falko Busse, Ph.D., President of its Bruker BioSpin Group, agreed that his executive duties would begin transitioning around May 1, 2026, with his employment at Bruker and Bruker BioSpin ending on October 3...
Business Operations and StrategyExecutive/Board Changes
Bruker Expands Board, Appoints Thierry Bernard as Director
Positive
Apr 1, 2026
On March 27, 2026, Bruker’s board voted to expand its size to 12 members and appointed Thierry L. Bernard, CEO and Managing Director of QIAGEN N.V., as a Class III director effective April 1, 2026, with a term running until the 2027 annual m...
Executive/Board ChangesDividends
Bruker Announces Board Changes and Declares Quarterly Dividend
Positive
Feb 20, 2026
On February 16, 2026, Bruker said board member Dr. Cynthia M. Friend will retire from the Board of Directors at the 2026 Annual Meeting when her current term as a Class II director expires, after serving since May 2016 and sitting on the Compensat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.